Stenotrophomonas maltophilia: Difference between revisions
From IDWiki
Stenotrophomonas maltophilia
m (Text replacement - "\[\[Oxidase test::(.*?)-(.*?)\]\]" to "$1 Oxidase::$2") |
(→) |
||
| Line 3: | Line 3: | ||
===Microbiology=== |
===Microbiology=== |
||
*Aerobic, non-fermentive, catalase [[Catalase::positive]], oxidase |
*Aerobic, non-fermentive, catalase [[Catalase::positive]], oxidase [[Oxidase::negative]], [[Stain::Gram-negative]] [[Cellular shape::bacillus]] |
||
*Multiple mechanisms of resistance |
*Multiple mechanisms of resistance |
||
**RND, MfsA, and Sme-related efflux pumps |
**RND, MfsA, and Sme-related efflux pumps |
||
Revision as of 19:23, 10 September 2020
Background
Microbiology
- Aerobic, non-fermentive, catalase positive, oxidase negative, Gram-negative bacillus
- Multiple mechanisms of resistance
- RND, MfsA, and Sme-related efflux pumps
- Sul or dfrA genes (TMP-SMX resistance)
- β-lactamases
- Aminoglycoside-modifying enzymes
Clinical Manifestations
- Nosocomial infections with high mortality and high antibiotic resistance
Management
- Limited antibiotic options
- Therapy should be guided by antimicrobial susceptibility testing
- Antistenotrophomonal antibiotics:
- TMP-SMX 15 mg/kg split q8h (preferred agent, if susceptible)
- Fluoroquinolones, including moxifloxacin, levofloxacin, and ciprofloxacin (though develops resistance quickly on monotherapy)
- Minocycline, doxycycline, and tigecycline
- Ticarcillin-clavulanate and ampicillin-sulbactam
- Ceftazidime and ceftazidime-avibactam
- Colistin, though high rates of resistance
- Possibly ceftriaxone
